Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2

The effect of EGF stimulation and its inhibition with gefitinib (‘Iressa’, ZD1839), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been investigated in two EGFR-positive human bladder tumour cell lines, RT112 and RT4. The growth of RT112 cells in a medium containing 10% fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nutt, J E, Lazarowicz, H P, Mellon, J K, Lunec, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409696/
https://www.ncbi.nlm.nih.gov/pubmed/15083203
http://dx.doi.org/10.1038/sj.bjc.6601768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409696/
https://www.ncbi.nlm.nih.gov/pubmed/15083203
http://dx.doi.org/10.1038/sj.bjc.6601768

Ejemplares similares